Literature DB >> 3362213

Identification of an altered splice site in Ashkenazi Tay-Sachs disease.

E Arpaia1, A Dumbrille-Ross, T Maler, K Neote, M Tropak, C Troxel, J L Stirling, J S Pitts, B Bapat, A M Lamhonwah.   

Abstract

Tay-Sachs disease is an autosomal recessive genetic disorder resulting from mutation of the HEXA gene encoding the alpha-subunit of the lysosomal enzyme, beta-N-acetylhexosaminidase A (ref. 1). A relatively high frequency of carriers (1/27) of a lethal, infantile form of the disease is found in the Ashkenazi Jewish population, but it is not yet evident whether this has resulted from a founder effect and random genetic drift or from a selective advantage of heterozygotes. We have identified a single-base mutation in a cloned fragment of the HEXA gene from an Ashkenazi Jewish patient. This change, the substitution of a C for G in the first nucleotide of intron 12 is expected to result in defective splicing of the messenger RNA. A test for the mutant allele based on amplification of DNA by the 'polymerase chain rection and cleavage of a DdeI restriction site generated by the mutation revealed that this case and two other cases of the Ashkenazi, infantile form of Tay-Sachs disease are heterozygous for two different mutations. The occurrence of multiple mutant alleles warrants further examination of the selective advantage hypothesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3362213     DOI: 10.1038/333085a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  48 in total

Review 1.  Molecular biology made easy. The polymerase chain reaction.

Authors:  A M Clarke; N P Mapstone; P Quirke
Journal:  Histochem J       Date:  1992-12

2.  Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations.

Authors:  R Asakai; D W Chung; O D Ratnoff; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

3.  Tay-Sachs disease heterozygote detection: use of a centrifugal analyser for automation of hexosaminidase assays with two different artificial substrates.

Authors:  E C Landels; I H Ellis; M Bobrow; A H Fensom
Journal:  J Med Genet       Date:  1991-02       Impact factor: 6.318

4.  Frequency of the Tay-Sachs disease splice and insertion mutations in the UK Ashkenazi Jewish population.

Authors:  E C Landels; I H Ellis; A H Fensom; P M Green; M Bobrow
Journal:  J Med Genet       Date:  1991-03       Impact factor: 6.318

5.  Distribution of three alpha-chain beta-hexosaminidase A mutations among Tay-Sachs carriers.

Authors:  E E Grebner; J Tomczak
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

6.  An intron binding protein is required for transformation ability of p53.

Authors:  S W Beenken; G Karsenty; L Raycroft; G Lozano
Journal:  Nucleic Acids Res       Date:  1991-09-11       Impact factor: 16.971

7.  Preimplantation single-cell analysis of multiple genetic loci by whole-genome amplification.

Authors:  M C Snabes; S S Chong; S B Subramanian; K Kristjansson; D DiSepio; M R Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

8.  Heterozygosity for Tay-Sachs disease in non-Jewish Americans with ancestry from Ireland or Great Britain.

Authors:  M van Bael; M R Natowicz; J Tomczak; E E Grebner; E M Prence
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

9.  Further investigation of the HEXA gene intron 9 donor splice site mutation frequently found in non-Jewish Tay-Sachs disease patients from the British Isles.

Authors:  E C Landels; P M Green; I H Ellis; A H Fensom; M M Kaback; J Lim-Steele; K Zeiger; N Levy; M Bobrow
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

10.  Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients.

Authors:  N Kamatani; M Hakoda; S Otsuka; H Yoshikawa; S Kashiwazaki
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.